Want to see JP:4570 full AI Analyst Report?
Immuno-Biological Laboratories Co., Ltd. (4570) AI Stock Analysis
Immuno-Biological Laboratories Co., Ltd.
(TSE/TYO:4570)
The company's excellent financial turnaround and fortress-like balance sheet are the primary drivers of the score. This is tempered by a mixed technical picture, where short-term momentum is positive but the stock remains in a longer-term downtrend, and a valuation that is not particularly cheap.
Immuno-Biological Laboratories Co., Ltd. (4570) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 9.56B
- Dividend Yield
- 0.58%
- Average Volume (3M)
- 127.70K
- Price to Earnings (P/E)
- 26.0
- Beta (1Y)
- 0.99
- Revenue Growth
- 13.46%
- EPS Growth
- 42.41%
- Country
- Japan
- Employees
- 54
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Immuno-Biological Laboratories Co., Ltd. Business Overview & Revenue Model
Company Description
Immuno-Biological Laboratories Co., Ltd. (IBL) is a global entity dedicated to the research, development, production, and distribution of immunological reagents. The company's diverse offerings include ELISA assay kits designed for the precise quanti...
Immuno-Biological Laboratories Co., Ltd. Financial Statement Overview
Summary
Excellent financial health with strong profitability (32.7% net margin), robust cash flow generation, and a very solid balance sheet with minimal debt (9.6% debt-to-equity). The only minor concern is a recent moderation in revenue growth.
Income Statement
85Very PositiveBalance Sheet
92Very PositiveCash Flow
90Very Positive| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.08B | 1.00B | 969.53M | 816.70M | 794.62M | 647.58M |
| Gross Profit | 777.51M | 700.28M | 628.34M | 517.29M | 526.71M | 376.70M |
| EBITDA | 368.36M | 299.82M | 226.55M | 128.11M | -279.54M | -127.50M |
| Net Income | 368.32M | 329.01M | 249.05M | 186.69M | -289.73M | -258.77M |
Balance Sheet | ||||||
| Total Assets | 2.23B | 2.16B | 1.85B | 1.62B | 1.43B | 1.71B |
| Cash, Cash Equivalents and Short-Term Investments | 907.94M | 989.47M | 825.73M | 734.14M | 614.16M | 508.35M |
| Total Debt | 171.81M | 177.09M | 204.23M | 235.98M | 234.99M | 234.00M |
| Total Liabilities | 338.30M | 311.75M | 332.03M | 354.25M | 355.72M | 336.99M |
| Stockholders Equity | 1.89B | 1.84B | 1.51B | 1.27B | 1.08B | 1.37B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 267.68M | 123.83M | 115.11M | 26.46M | -93.20M |
| Operating Cash Flow | 0 | 301.09M | 183.50M | 133.78M | 26.46M | -93.20M |
| Investing Cash Flow | 0 | -116.46M | -53.66M | -24.50M | 30.04M | -155.63M |
| Financing Cash Flow | 0 | -27.14M | -31.75M | 991.00K | 991.00K | 144.00M |
Immuno-Biological Laboratories Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4570, the sentiment is Negative. The current price of 1009.00 is below the 20-day moving average (MA) of 1062.25, below the 50-day MA of 1094.32, and below the 200-day MA of 1244.80, indicating a bearish trend. The MACD of -23.95 indicates Positive momentum. The RSI at 43.03 is Neutral, neither overbought nor oversold. The STOCH value of 76.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4570.
Immuno-Biological Laboratories Co., Ltd. Peers Comparison
Overall Rating
- JP:457078Outperform
JP:497845Neutral
JP:777442Neutral
JP:459938Underperform
JP:777637Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:4570 | 78Outperform | JPY 9.56B | 25.97 | ― | 0.58% | 13.46% | 42.41% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| JP:4978 | 45Neutral | JPY 13.03B | -26.58 | ― | ― | -18.71% | -246.54% |
| JP:7774 | 42Neutral | JPY 25.54B | -58.02 | ― | ― | 3.43% | -53.59% |
| JP:4599 | 38Underperform | JPY 8.71B | -4.68 | ― | ― | ― | 4.85% |
| JP:7776 | 37Underperform | JPY 7.43B | -6.49 | ― | ― | -56.16% | 3.12% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4570 | Immuno-Biological Laboratories Co., Ltd. | 1027.00 | 563.99 | 121.81% | |
| JP:4599 | StemRIM Inc. | 139.00 | -134.00 | -49.08% | |
| JP:4978 | ReproCELL Inc. | 122.00 | -51.00 | -29.48% | |
| JP:7774 | Japan Tissue Engineering Co., Ltd. | 629.00 | 153.00 | 32.14% | |
| JP:7776 | CellSeed Inc. | 188.00 | -249.00 | -56.98% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 08, 2026